Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.67 |
| ▸ | RRM1 | P23921 | 1/20 | 0.66 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.62 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.62 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.62 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.57 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.57 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.57 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.57 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.50 |
| ▸ | FNTA | P49354 | 1/20 | 0.50 |
| ▸ | FNTB | P49356 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27183085 | 1.00 | DPP7 (0.67) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL1977809 | 1.00 | DPP7 (0.67) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL7769958 | 1.00 | DPP7 (0.67) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL31157642 | 1.00 | DPP7 (0.67) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL7770773 | 1.00 | DPP7 (0.67) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL7769954 | 1.00 | DPP7 (0.67) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL3876752 | 1.00 | DPP7 (0.67) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL1978591 | 1.00 | DPP7 (0.67) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL1976979 | 1.00 | DPP7 (0.67) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL16124667 | 0.98 | DPP7 (0.69) | DPP7RRM1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | MARS, INCORPORATED (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4593631-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | Mars, Incorporated (US) | 2025-08-06 | — | — | EP | disclosed |
| CN-119968127-A | Animal food compositions with improved palatability and customizable properties and methods of making the same | 玛氏公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2024073025-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | MARS, INCORPORATED (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-4344552-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY, AND METHODS FOR PREPARING THE SAME | MARS, INCORPORATED (US) | 2024-04-03 | — | — | EP | disclosed |
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | DPP7 3332/4885RRM1 3946/4885GNAI3 769/4885 |
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | PIGS, TAS2R13, CEL | DPP7 321/4885RRM1 3986/4885GNAI3 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.